generic glp-1 drugs Diabetes patients now have access to first medication: ‘More accessible and affordable’ GLP-1 SOS™ Digestive Support for

Semaglutide for treatment of obesity in hemodialysis patients waiting for a kidney transplant: New hope

Their popularity in Hollywood and among public figures has led to a rapid surge in demand for the drugs

Key Points Native human GLP-1 normalizes hyperglycaemia in patients with type 2 diabetes mellitus, but the short in vivo half-life of this hormone limits its therapeutic application A number of synthetic GLP-1 receptor agonists, with half-lives between 23 h and several days, have been developed for the long-term treatment of type 2 diabetes mellitus Short-acting GLP-1 receptor agonists (such as exenatide and lixisenatide) predominantly lower postprandial glucose levels and insulin concentrations via retardation of gastric emptying Long-acting GLP-1 receptor agonists (such as albiglutide, dulaglutide, exenatide long-acting release and liraglutide) predominantly lower blood glucose levels through stimulation of insulin secretion and reduction of glucagon levels Adverse effects of GLP-1 receptor agonists include nausea, vomiting and diarrhoea, injection-site reactions, antibody formation and increased heart rate This is a preview of subscription content, access via your institution Access options Subscribe to this journal Receive 12 print issues and online access 119.00 per year only 9.92 per issue Buy this article Purchase on SpringerLink Instant access to the full article PDF

A patient in the 24% federal tax bracket who spends $1,788 annually on semaglutide injection (starting at $149/month) avoids approximately $429 in combined federal and FICA taxeseffectively lowering the actual cost of treatment

S., Bueno, A